Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Filings indexed 1,237 across all filing types
Latest filing 2025-11-06 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Please find attached the unaudited standalone and consolidated financial results for the quarter and half yearly ended September 30, 2025.
Regulatory Filings
2025-11-06 English
Outcome of Board Meeting
Regulatory Filings
2025-11-06 English
Outcome of Board Meeting
Regulatory Filings
2025-11-06 English
Please find attached herewith the Outcome of Board Meeting held on Thursday, November 06, 2025.
Regulatory Filings
2025-11-06 English
We would like to inform you that the ESOP Allotment Committee at its meeting held today i.e. November 05, 2025, has approved the allotment of 33670 equity shares of face value Re. 1/- each ....
Share Issue/Capital Change Classification · 100% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the allotment of shares under the company's Employee Stock Options Plan (ESOP) 2019. It details the number of shares allotted, the increase in issued share capital, and regulatory compliance under SEBI regulations. The document is an announcement of a share allotment event, specifically related to employee stock options, and includes details such as share numbers, exercise price, lock-in period, and ISIN. It is not a financial report, earnings release, or management discussion, but rather a formal notification of a capital change due to share allotment. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length is 4148 characters, which is consistent with an announcement rather than a full report.
2025-11-05 English
Allotment of Securities
Share Issue/Capital Change Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the allotment of shares under the company's Employee Stock Options Plan (ESOP) 2019. It details the number of shares allotted, the increase in issued share capital, and regulatory compliance under SEBI regulations. The document is notifying the exchanges about a capital change event (share allotment under ESOP), including specifics such as share numbers, exercise price, lock-in period, and ISIN. It is not a full financial report, earnings release, or management discussion, but rather an announcement of a capital change event. The document length is 4148 characters, which is relatively short and focused on the share allotment event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.